- Home
- GOOD vs SLBT Comparison
GOOD vs SLBT Comparison
Compare GOOD & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOOD | SLBT |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.9M | 644.9M |
| IPO Year | 2003 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GOOD | SLBT |
|---|---|---|
| Price | $9.98 | $0.75 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.88 | N/A |
| AVG Volume (30 Days) | ★ 673.7K | 52.3K |
| Earning Date | 11-03-2026 | 10-26-2026 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | $123.88 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $9.89 | $0.62 |
| 52 Week High | $13.28 | $6.25 |
Technical Indicators
Market Signals| Indicator | GOOD | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 22.02 | 27.09 |
| Support Level | N/A | N/A |
| Resistance Level | $13.07 | $1.75 |
| Average True Range (ATR) | 0.35 | 0.15 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 11.80 | 15.42 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.